Philippe Dro

Anesthesiology
Themis Bioscience
Austria

Business Expert Anesthesiology
Biography

  In the last 20 years Philippe Dro initiated and executed several strategic transactions. Prior to its acquisition by GSK, he served at the vaccine developer GlycoVaxyn AG as CEO and member of the Supervisory Board. Before that, he led EndoArt S.A., a medtech company, in the position of CEO and Chairman of the Board through a successful sale process of the company to Allergan. When Actelion acquired Axovan AG, he was acting CFO and Head of Business Development. Prior to that, he served at Novartis, Skyepharma and Antares Pharma in a number of responsible functions.

Research Intrest

 biochemistry, vaccines, anesthesiology